Cyclooxygenase 2 Promoter-based replication-selective adenoviral vector for hypopharyngeal cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 3, 2009, Pages 282-286

  Nakagawa, Takahiro ^a   Tanaka, Hironori ^b   Shirakawa, Toshiro ^b   Gotoh, Akinobu ^c   Hayashi, Yoshitake ^b   Hamada, Katsuyuki ^d   Tsukuda, Mamoru ^e   Nibu, Ken Ichi ^a,b  

^a Department of Otolaryngology Head and Neck Surgery ^*  (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLOOXYGENASE 2;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL STRAIN H891; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; JAPAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UNIVERSITY HOSPITAL; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BIOPSY; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; DISEASE PROGRESSION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 63049090046     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2008.549     Document Type: Article

References (27)

1. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000; 6(10):1134-1139.
2. Shirakawa T, Hamada K, Zhang Z, et al. A cox-2 promoter-based replication- selective adenoviral vector to target the cox-2-expressing human bladder can- cercells. Clin Cancer Res. 2004;10(13):4342-4348.
3. Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K. A replication- selective adenoviral vector for head and neck cancers. Arch Otolaryngol Head Neck Surg. 2005;131(7):630-634.
4. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(5): 991-994.
5. Kömhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high-grade human transitional cell bladder carcinomas. Am J Pathol. 2000;157(1):29-35.
6. Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep. 2007;17(2):289-295.
7. McKinnon RD, Bacchetti S, Graham FL. Tn5 mutagenesis of the transforming genes of human adenovirus type 5. Gene. 1982;19(1):33-42.
8. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology. 1988; 163(2):614-617.
9. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91(19):8802-8806.
10. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours (UICC). 6th ed. New York, NY: Wiley-Liss; 2002.
11. Barnes L, Eveson J, Reichart P, Sidransky D, eds. Pathology and Genetics of Head and Neck Tumours (World Health Organization Classification of Tumours). Geneva, Switzerland: World Health Organization; 2005.
12. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55(17):3785-3789.
13. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000;89(3):589-596.
14. Nakashima T, Maehara Y, Kohnoe S, Hayashi I, Katsuta Y. Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinomas. Head Neck. 1990;12(5):406-410.
15. Stausbøl-Grøn B, Bentzen SM, Jorgensen KE, Nielsen OS, Bundgaard T, Overgaard J. In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data. BrJ Cancer. 1999;79(7-8):1074-1084.
16. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10(16):5299-5312.
17. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCartyTM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol. 2000; 7(8):588-592.
18. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX- 015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6(8): 879-885.
19. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001;8(10):746-759.
20. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication- selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62(21):6070-6079.
21. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 1999;286(5448):2244-2245.
22. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000; 60(22):6359-6366.
23. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19(2):289-298.
24. Ko SH, Choi GJ, Lee JH, Han YA, Lim SJ, Kim SH. Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apopto- sis in oral squamous cell carcinoma. Oncol Rep. 2008;19(2):425-433.
25. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci. 2007;3(5):328-334.
26. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003;125(2):404-412.
27. Bardou M, Barkun AN, Ghosn J, Hudson M, Rahme E. Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol. 2004;2(10):880-887.